The clinical significance of abnormal serum Mg concentrations, mainly hypomagnesemia, and the advantage of routine determination of Mg2 , especially in hospitalized patients, have previously been emphasized [2, 3] . A simple assay with good performance is, therefore, fundamental. Various methods for the detection of serum Mg are available, including titan yellow, fluorometry, atomic absorption spectrophotometry (AAS), ion chromatography, and spectrophotome- However, interferences have been reported with this approach and the reagents used may be very unstable [4] .
Several assays based on the enzymatic determination of Mg2 ± have been developed. Over 300 enzymes can be activated by Mg [5] , and Mg assays developed so far include those involving hexokinase [6] , glucokinase [7] , glycerol kinase [8] , and phosphoglucomutase [9] . Certain drawbacks such as long assay times and interferences, however, may not make them ideal for routine use. The proposed enzymatic kit is a simple and new method for Mg determination based on the activation of isocitrate dehydrogenase (lCD; EC 1. Comparison method. We used a xylidyl blue spectrophotometric method [13] applied to the Cobas Mira analyzer and AAS [14] applied to the Varian AA1275 to measure Mg concentration for comparisons with the proposed assay.
A reaction profile was obtained in the same way, but absorbances were read every 60 s for 845 s. A blank of distilled water was measured in duplicate with each analytical run and then averaged and subtracted from every result.
Results
Reaction profile. Fig. 1 Discussion lCD was chosen for this assay as an NADP-specific enzyme, activated by Mg2 ± and producing NADPH, which absorbs at 340 nm in the presence of the substrate potassium isocitrate [16] . It is a simple, one-step reaction, compared with previous assays that involve at least two enzymatic steps [6] [7] [8] [9] . The lCD,
Mg (mmol/L) using Xylidyl Blue method Recoveiy. We assessed recovery by adding one volume of an aqueous solution of Mg (at 2.5, 5, and 10 mmol/L) to nine volumes of serum from patients with renal failure (creatinine 657-98 1 imoUL), liver disease (bilirubin .tmolJL,
and from apparently healthy patients, to give a final concentration of 0.25, 0.5, and 1 mmol/L Mg. Ten serum samples of each were tested in duplicate. Recoveries are shown in Table 2 . Recoveries were also undertaken in an aqueous saline solution.
The mean recovery in an aqueous medium was 8% higher than that obtained with the serum matrix. interference. Hemolysis interfered with the assay. The effect of these on potential recovery is illustrated in Table 3 . Protein up to 109
Interferences
g/L (maximum tested) showed no interference when comparing results from the proposed method and xylidyl blue technique with a range of samples obtained from patients with myeloma. Mg binds quickly to the enzyme, deeming an incubation before reaction unnecessary, eliminating a lag phase, and therefore keeping the total assay time to a minimum (4 mm). In comparison, the method reported by Tabata et al. [6] has a total assay time of 20 mm. The other enzymatic Mg assays developed since require considerably shorter assay times. However, these have other drawbacks, such as the method by Wimmer et al. [8] , which has certain interferences.
We have shown that the proposed assay performs well. It is linear to at least 5 mmol/L, so samples would rarely need diluting to fall within this range. The method by Wimmer et al.
[8] is only linear up to 2 minol/L and that of Fossati et al. [7] up to 2.06 nimollL. Mg concentrations above these concentrations need to be diluted and reassayed. We have shown good precision, within-run CVs between 1.4% and 3.5% and day to day CVs between 3.2% and 5.4%, and good accuracy; the method compares well with the xylidyl blue spectrophotometric method and AAS. Deviation from a slope of 1.0 between the proposed and comparison methods is probably due to viscosity differences between serum samples and the aqueous calibrator, shown by a greater recovery of Mg with an aqueous matrix when compared with a serum matrix. This would be overcome by using a serum-based calibrator for the automated method. The proposed assay is specific to Mg despite the addition of metal ions well above normal serum concentrations. High bilirubin, lipid, and protein concentrations do not interfere with the assay, although hemoglobin appears to reduce the apparent Mg concentration in the sample. However, in view of the fact that there is a high concentration of Mg in erythrocytes, the negative interference is probably greater than that found in the experiments reported. These observations not withstanding, it is advisable not to use samples in which there is obvious hemolysis for the assessment of serum Mg [5, 17] . The assay is not affected by endogenous compounds found in blood from patients with renal failure or endogenous lCD found at increased concentrations in sera from patients with liver disease. The reagents were stable for at least a month at 4 #{176}C and also required no preparation before use. With the assay requiring only two reagents and calibration values stable enough for use of a stored calibration facility, the method is easily adapted to automated clinical analyzers and may be used as an alternative to current methods for both routine and stat analysis.
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